Enliven Therapeutics, Inc. (ELVN)
NasdaqGS · USD · Healthcare · Biotechnology
$41.49 (-0.07%) as of
Key statistics
- Market cap
- 3.04B
- Forward P/E
- -17.90
- EPS (TTM)
- -1.67
- Dividend yield
- 0.00%
- 52-week range
- 14.78 – 62.32
- Beta
- 0.34
- Profit margin
- 0.00%
- Analyst target
- $74.42
- Volume
- 2.32M
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boulder, CO, United States
- Employees
- 67
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.